secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021559
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q3 net loss $113.2M; NTLA-2001 shows 93% TTR reduction, NTLA-2002 91% attack reduction
--------------------------------------------------------------------------------

- Net loss of $113.2M in Q3 2022 widened from $71.6M in Q3 2021; cash position $848.7M.
- Collaboration revenue rose to $13.3M from $7.2M; R&D expenses increased to $96.7M.
- NTLA-2001: mean serum TTR reductions of 93% (0.7 mg/kg) and 92% (1.0 mg/kg) at day 28.
- NTLA-2002: 25 mg dose led to 91% mean reduction in HAE attacks through 16-week observation.
- Expects to initiate NTLA-2002 Phase 2 in 1H 2023; plans IND filing for NTLA-3001 in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017022021559/0000950170-22-021559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017022021559/ntla-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer